TD Waterhouse Canada Inc. Has $2.77 Million Position in IQVIA Holdings Inc. $IQV

TD Waterhouse Canada Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 79.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,640 shares of the medical research company’s stock after buying an additional 6,033 shares during the period. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $2,772,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in IQV. Apella Capital LLC grew its stake in shares of IQVIA by 5.1% during the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 58 shares during the period. Quadrant Capital Group LLC lifted its holdings in IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares during the period. Breakwater Capital Group increased its stake in shares of IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after purchasing an additional 64 shares in the last quarter. Finally, First Growth Capital LLC raised its position in shares of IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 68 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by company insiders.

IQVIA Trading Down 0.2%

Shares of NYSE IQV opened at $267.34 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $271.80. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The business’s 50 day moving average is $232.02 and its two-hundred day moving average is $193.57. The stock has a market capitalization of $44.00 billion, a P/E ratio of 33.17, a PEG ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IQV. Robert W. Baird upped their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. BMO Capital Markets boosted their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Finally, TD Cowen boosted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.62.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.